NEWS & PUBLICATIONS
LATEST UPDATES
At BIOHK 2026 in Hong Kong, co-founder and CEO Andy Xian Zeng, Ph.D., presented Byterna’s integrated strategy spanning transient, non-integrating in vivo CAR-T and AI-guided personalized neoantigen cancer vaccines.
Read update
Byterna, Insilico Medicine and Dune Quantum announced a collaboration connecting generative AI, heterogeneous quantum computing and programmable circular mRNA development.
Read update
At the 2026 Asia-Pacific RNA Excellence Awards ceremony in Singapore, Byterna CEO Andy Xian Zeng received the 2025 RNA Excellence Award for the Greater China Region.
Read updateCOMPANY & RESEARCH
The financing supports BR101 development and continued investment in Byterna’s personalized cancer-vaccine and programmable mRNA capabilities.
Joint preclinical work with Fudan University was selected for poster presentation at the Chinese Antibody Society (ChAbS) Annual Conference 2026.
At RNA Therapeutics & Manufacturing Asia, Byterna discussed circular mRNA innovation and in vivo CAR-T development.
Byterna announced Angel and Angel+ financing with investment from SunNovo Pharma and Efung Capital, supporting its circular mRNA and in vivo CAR-T pipeline.
Byterna presented preclinical work on circular mRNA-based CAR-T pharmacology and its potential for in vivo immune-cell programming.
Byterna announced municipal R&D support for circular RNA sequence design and chemical-modification research.
The financing supported the development of an AI-powered circular mRNA drug discovery platform.
PEER-REVIEWED SCIENCE
J. Chem. Inf. Model. 2025, 65, 6568–6584
This computational-methods study introduces RIdiffusion and reports benchmark performance on 3D RNA inverse-folding datasets.
Authors listing Byterna Therapeutics as an affiliation: Shuai Zhang, Mengyao Ma and Hui Zhao. Xian Zeng lists Fudan University in the paper and is now with Byterna.Read in ACS Publications
Signal Transduction and Targeted Therapy 10, 411 (2025)
This preclinical study used ex vivo-engineered primary human T cells and evaluated CAR expression, in vitro function and antitumor activity in mouse models.
Byterna-affiliated co-author: Hui Zhao.Read in NatureMEDIA & SCIENTIFIC ENQUIRIES
